ABAntonio Burgos

Antonio Burgos

*This is an algorithmically generated author record based on publicly available information.

Antonio Burgos has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Exploratory Genomic Characterisation of the Resistome, Virulome and Molecular Epidemiology of Multidrug-Resistant Klebsiella pneumoniae Clinical Isolates from Four Peruvian Regions

    by Karen Quispe Oré, Alberto Salazar-Granara, Mario Cueva Távara, Janet Huancachoque Molina, Diego Segura-Loayza, Daisy Obispo Achallma, Guillermo Liendo Aguirre, Antonio Burgos Espejo, Alexander Briones Alejos, Sheyber Lifonzo Mucha, et al.

    Multidrug-resistant (MDR) Klebsiella pneumoniae is a critical cause of nosocomial infections associated with high mortality. Of particular concern is the genomic convergence of multidrug resistance and hypervirulence (MDR-hvKP), which represents a severe public health threat. This study characterised the resistome, virulome, and population structure of seven clinical MDR K. pneumoniae isolates collected between 2024 and 2025 across four Peruvian regions (Moquegua, Ucayali, Loreto, and Lima) using whole-genome sequencing (WGS). Genomic analysis identified six distinct sequence types, with the high-risk clone ST307 being the most prevalent (2/7 isolates), consistently associated with the KL102 capsular locus. Remarkably, one isolate from Loreto (oph_54) exhibited a convergent MDR-hvKP genomic profile (ST218, KL57, virulence score 4), carrying yersiniabactin, salmochelin (iro), and aerobactin (iuc) loci alongside multiple resistance determinants. The isolates presented a robust resistome dominated by the extended-spectrum beta-lactamase gene blaCTX-M-15 (5/7) and blaOXA-1, coupled with aac(6′)-Ib-cr and fosA6 genes. Plasmid analysis revealed a predominance of IncFIB(K) replicons. Although exploratory, these findings demonstrate the regional presence of high-risk ST307 lineages and the emergence of convergent MDR-hvKP genomic profiles within the analysed Peruvian hospitals. Immediate and continuous genomic surveillance is urgently required to monitor the potential spread of these highly dangerous, MDR bacterial lineages within these healthcare environments.

  • Open Access

    Prevalence of Antimicrobial Resistance in Gram-Negative Bacteria Bloodstream Infections in Peru and Associated Outcomes: VIRAPERU Study

    by Fiorella Krapp, Coralith García, Noemi Hinostroza, Lizeth Astocondor, Claudia R. Rondon, Brecht Ingelbeen, Hugo A. Alpaca-Salvador, Catherine Amaro, Carla Aguado Ventura, Evelyn Barco-Yaipén, et al.

    : Surveillance of antimicrobial resistance among gram-negative bacteria (GNB) is of critical importance, but data for Peru are not available. To fill this gap, a non-interventional hospital-based surveillance study was conducted in 15 hospitals across Peru from July 2017 to October 2019. Consecutive unique blood culture isolates of key GNB (Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter spp.) recovered from hospitalized patients were collected for centralized antimicrobial susceptibility testing, along with linked epidemiological and clinical data. A total of 449 isolates were included in the analysis. Resistance to third-generation cephalosporins (3GCs) was present in 266 (59.2%) GNB isolates. Among E. coli (n = 199), 68.3% showed 3GC resistance (i.e., above the median ratio for low- and middle-income countries in 2020 for this sustainable development goal indicator). Carbapenem resistance was present in 74 (16.5%) GNB isolates, with wide variation among species (0% in E. coli, 11.0% in K. pneumoniae, 37.0% in P. aeruginosa, and 60.8% in Acinetobacter spp. isolates). Co-resistance to carbapenems and colistin was found in seven (1.6%) GNB isolates. Empiric treatment covered the causative GNB in 63.3% of 215 cases. The in-hospital case fatality ratio was 33.3% (92/276). Pseudomonas aeruginosa species and carbapenem resistance were associated with higher risk of in-hospital death. In conclusion, an important proportion of bloodstream infections in Peru are caused by highly resistant GNB and are associated with high in-hospital mortality.


  • Underutilization and Quality Gaps in Blood Culture Processing in Public Hospitals of Peru

    by Fiorella Krapp, Claudia Rondon, Catherine Amaro, Evelyn Barco-Yaipén, María Valera-Krumdieck, Rubén Vásquez, Alexander Briones, Martin Casapia, Antonio Burgos, Favio Sarmiento López, et al.

    : Correct processing of blood cultures may impact individual patient management, antibiotic stewardship, and scaling up of antimicrobial resistance surveillance. To assess the quality of blood culture processing, we conducted four assessments at 16 public hospitals across different regions of Peru. We assessed the following standardized quality indicators: 1) positivity and contamination rates, 2) compliance with recommended number of bottles/sets and volume of blood sampled, 3) blood culture utilization, and 4) possible barriers for compliance with recommendations. Suboptimal performance was found, with a median contamination rate of 4.2% (range 0–15.1%), with only one third of the participating hospitals meeting the target value of < 3%; and a median positivity rate of 4.9% (range 1–8.1%), with only 6 out of the 15 surveilled hospitals meeting the target of 6–12%. None of the assessed hospitals met both targets. The median frequency of solitary blood cultures was 71.9% and only 8.9% (N = 59) of the surveyed adult bottles met the target blood volume of 8 – 12 mL, whereas 90.5% (N = 602) were underfilled. A high frequency of missed opportunities for ordering blood cultures was found (69.9%, 221/316) among patients with clinical indications for blood culture sampling. This multicenter study demonstrates important shortcomings in the quality of blood culture processing in public hospitals of Peru. It provides a national benchmark of blood culture utilization and quality indicators that can be used to monitor future quality improvement studies and diagnostic stewardship policies.